Egyptian European Pharmaceutical Industry v. Regents of the University of Michigan

CourtDistrict Court, E.D. Michigan
DecidedOctober 6, 2021
Docket2:20-cv-13409
StatusUnknown

This text of Egyptian European Pharmaceutical Industry v. Regents of the University of Michigan (Egyptian European Pharmaceutical Industry v. Regents of the University of Michigan) is published on Counsel Stack Legal Research, covering District Court, E.D. Michigan primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Egyptian European Pharmaceutical Industry v. Regents of the University of Michigan, (E.D. Mich. 2021).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION EGYPTIAN EUROPEAN PHARMACEUTICAL INDUSTRY, et al., Case No. 2:20-cv-13409 Honorable Laurie J. Michelson Plaintiff,

v.

MARK L. DAY

Defendant.

OPINION AND ORDER GRANTING IN PART AND DENYING IN PART DEFENDANT’S MOTION TO DISMISS [16] Egyptian European Pharmaceutical Industry (“EEPI”) and Dr. Layla Fakhr El-Din El-Sawy sought to collaborate with Dr. Mark Day at the University of Michigan to research the properties of A. maritima, a plant native to Egypt, and jointly develop a cancer drug. But, instead of a fruitful collaboration, EEPI and El- Sawy allege that Day discriminated against El-Sawy because she is an Egyptian, Muslim woman and a naturalized United States citizen. Plaintiffs also complain that Day interfered with EEPI and El-Sawy’s relationship with the University, used unreliable research methods, and failed to provide accurate and scientifically sound reports on his research. Day’s actions, Plaintiffs say, harmed El-Sawy’s reputation and career prospects, exacerbated her cardiac issues, and caused EEPI to waste money on flawed research. So EEPI and El-Sawy brought this suit against Day, alleging constructive discharge, hostile work environment, violation of First Amendment rights, retaliation, tortious interference, breach of contract, and fraud and/or negligent

misrepresentation. As Plaintiffs’ hostile-work-environment claim and Establishment Clause claim are barred by the statute of limitations, the Court will GRANT Day’s motion to dismiss with respect to Counts II and III. The Court will also GRANT Day’s motion to dismiss Count I with respect to EEPI and Count VII with respect to El- Sawy. Day’s motion will otherwise be DENIED.

Because Day seeks dismissal under Federal Rule of Civil Procedure 12(b)(6), the Court accepts the factual allegations in EEPI and El-Sawy’s complaint as true and draws reasonable inferences from those allegations in Plaintiffs’ favor. Waskul v. Washtenaw Cty. Cmty. Mental Health, 979 F.3d 426, 440 (6th Cir. 2020). EEPI is an Egyptian company that researches, develops, markets, and distributes pharmaceutical products. (ECF No. 14, PageID.250.) Pharco is its parent

company. (PageID.268.)1 El-Sawy is a biologist who primarily focuses on cancer research at EEPI. (PageID.256.) El-Sawy and her father, Mohammed El-Sawy, who is also a biologist, researched and developed medicinal uses for Ambrosia maritima (“A. maritima”).

1 All record citations are to ECF No. 14, unless otherwise indicated. (PageID.256–257.) A. maritima is a native Egyptian plant that has been used in traditional medicine to treat a variety of illnesses, including cancer. (Id.) Dr. Mark Day is a University of Michigan scientist who operates the Day

Laboratory within the University’s Department of Urology. (PageID.250.) El-Sawy first met Dr. Mark Day while she was volunteering at Day Lab in 2010 as a student. (PageID.257.) El-Sawy connected Day to her father and other senior management at EEPI to collaborate on further research involving A. maritima and determine whether the plant could be a source of anti-cancer compounds. (PageID.258.) EEPI and the Regents of the University of Michigan entered into a series of agreements to this end. (PageID.258–263.) The first agreement, executed on June 14,

2012, names Day as the Project Director of a one-year preliminary study of A. maritima (“First Research Agreement”). (PageID.258.) Satisfied with the results of the initial study, EEPI and the Regents extended the First Research Agreement through June 30, 2016 (“Amendment No. 1”). (PageID.259.) Also, on July 1, 2015, EEPI and the Regents entered into a second agreement, which provides that Day would be the Principal Investigator for a preclinical investigation of A. maritima

(“Second Research Agreement”). (PageID.261.) The purpose of this study was to allow EEPI to develop a drug for the treatment of bladder (as well as prostate and breast) cancer from the compounds in A. maritima and market this drug in the United States. (PageID.263–264.) The Second Research Agreement includes a reporting provision where the Regents agreed to provide EEPI with written program reports and a final report. (ECF No. 14-4, PageID.343.) It also includes a provision stating that Day and his research staff will train El-Sawy on various aspects of the research. (Id.) EEPI and Pharco also entered into a consulting agreement with Day. (PageID.259–260.) In 2015, per the Second Research Agreement, El-Sawy came to Day Lab to

work on the A. maritima preclinical research and receive training from Day. (PageID.265.) It was at this point, according to Plaintiffs, that Day began a “discriminatory campaign” against El-Sawy that was motivated by Day’s “contempt” for El Sawy because she is an Egyptian, Muslim woman and a naturalized U.S. citizen. (Id.) Plaintiffs allege that Day made discriminatory and threatening comments toward El-Sawy, including “I am a white guy in the United States and I can do whatever the hell I want” and that “I am a Western man and you can’t touch

me.” (PageID.266.) Day also used profane language toward El-Sawy on multiple occasions, which he did not use toward her white, male colleagues. (PageID.267.) Day also approved and endorsed attempts by his wife, Catherine Day, who was also El- Sawy’s co-worker, to convert El-Sawy to Christianity. (PageID.267–268.) Plaintiffs also claim that, during the preclinical study, Day made a number of false statements about the research. Day told EEPI that because his supplies of A.

maritima were running short, he needed to explore other sources of the chemical compound found in the plant. (PageID.318.) Day charged the “extravagant” expenses for these trips to EEPI. (Id.) But, Plaintiffs believe that the supply of A. maritima EEPI provided Day was sufficient for the preclinical study, rendering his trips unnecessary. (Id.) Day also told EEPI that another plant, A. hispida, would be a suitable substitute for A. maritima in the preclinical study before he performed a direct “head-to-head” study to compare the two plants. (PageID.319.) And, according to Plaintiffs, Day falsely stated that “his experiments had generated positive, replicable results which could be used in the further redevelopment of an anti-cancer

drug.” (PageID.321.) Events escalated on August 30, 2017. A few days prior, Day was quoted in an article, and EEPI believed that he revealed confidential information in violation of its agreement with the University. (PageID.268.) In fact, senior management at Pharco (EEPI’s parent company) sent Day an email stating he had breached the agreement between EEPI and the University. (PageID.268–269.) In response, Day sent seven emails that day to senior management at EEPI and to El-Sawy, threatening to

invalidate the patent, not credit EEPI or El-Sawy when publishing papers or articles on the research, and to litigate the University’s claim to the intellectual property “very aggressively.” (PageID.269–271.) Between August 30 and September 6, 2017, Day sent 48 messages of various forms to El-Sawy. (PageID.271–278.) Among these messages, Day stated that he removed El-Sawy’s access to the research data and threatened to report EEPI and El-

Sawy to the Ministry of Health in Egypt. (PageID.273.) Day also threatened to make sure El Sawy “will never work in science in the US” and ordered his laboratory staff to cease all communications with El-Sawy and EEPI. (PageID.274–275.) Day also threatened that if he had to fly to Egypt and address this with EEPI and El-Sawy in person, “it won’t be pretty” (PageID.274.) Plaintiffs allege that Day’s behavior was motivated by his animus against El-Sawy.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Jones v. Bock
549 U.S. 199 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Freddie Sevier v. Kenneth Turner
742 F.2d 262 (Sixth Circuit, 1984)
Heinrich v. Waiting Angels Adoption Services, Inc.
668 F.3d 393 (Sixth Circuit, 2012)
HDC, LLC v. City of Ann Arbor
675 F.3d 608 (Sixth Circuit, 2012)
Bruce Collyer v. Gregory Darling
98 F.3d 211 (Sixth Circuit, 1997)
Lawsuit Financial, LLC v. Curry
683 N.W.2d 233 (Michigan Court of Appeals, 2004)
Jenkins v. Southeastern Michigan Chapter, American Red Cross
369 N.W.2d 223 (Michigan Court of Appeals, 1985)
Hall v. Spencer County, Ky.
583 F.3d 930 (Sixth Circuit, 2009)
Bassett v. National Collegiate Athletic Ass'n
528 F.3d 426 (Sixth Circuit, 2008)
Blazer Foods, Inc v. Restaurant Properties, Inc
673 N.W.2d 805 (Michigan Court of Appeals, 2004)
Health Call of Detroit v. Atrium Home & Health Care Services, Inc
706 N.W.2d 843 (Michigan Court of Appeals, 2005)
Unibar Maintenance Services, Inc v. Saigh
769 N.W.2d 911 (Michigan Court of Appeals, 2009)
Hi-Way Motor Co. v. International Harvester Co.
247 N.W.2d 813 (Michigan Supreme Court, 1976)
Cataldo v. United States Steel Corp.
676 F.3d 542 (Sixth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Egyptian European Pharmaceutical Industry v. Regents of the University of Michigan, Counsel Stack Legal Research, https://law.counselstack.com/opinion/egyptian-european-pharmaceutical-industry-v-regents-of-the-university-of-mied-2021.